DIERKS + BOHLE

Comment: This medical law boutique still counts among the leading firms thanks to its excellent connections in the industry and in-depth, extensive knowledge. Praising the name partner, one client remarked, “Besides the high level of expertise on market access in Germany, Dierks also has a good instinct for political matters and assesses what is enforceable.” Drawing on this knowledge, the team advises on emerging topics earlier and more systematically than competitors in an industry driven by a steady flow of new regulations and legislative changes; hence it is often involved in important precedent proceedings. D+B continues to provide extensive advice in AMNOG proceedings – an area in which Nitz esp. has built up an outstanding reputation. However, the departure of another partner did not go unnoticed in the market: Daniel Geiger (“his departure would be a loss for any firm”, competitor) is starting his own business together with an associate from the firm. This weakens D+B in compliance and criminal law advice – an area that is picking up pace in view of the new legal framework. The firm reacted immediately by appointing a long-standing associate with expertise in precisely this field as partner. All it has to do now is to keep all its remaining partners together.
Strengths: Social law and healthcare policy issues; law on the reorganization of the pharmaceuticals market (AMNOG).
Recommended: Prof. Dr. Dr. Christian Dierks, (“responds quickly”, client), Dr. Ulrich Grau, Dr. Gerhard Nitz (“pleasant, creative legal approach”, competitor).
Practice: All-round activity in medical law. Emphasis on pharma law in advice on reimbursement of costs and negotiations with health insurance companies, incl. litigation. Also pharma compensation claims, distribution, due diligence, pharma advertising and business compliance, approval and integration of products into the healthcare system. Second pillar in physicians’ and hospital law. Clients: primarily market leaders in the pharmaceutical sector, also manufacturers of medical products. (Core team: 6 equity partners, 3 salary partners, 9 associates)
Clients: ?? Lundbeck in interim legal protection proceedings in connection with AMNOG arbitration award and on reimbursement concerning vortioxetine; PTC Therapeutics on reimbursement and arbitration proceedings concerning orphan drug; Alexion on reimbursement concerning orphan drugs; regulatory advice to investor on acquisition of Aposan; various pharmaceutical companies in AMNOG proceedings on market entry.
  • Teilen